DAX25.023 -1,0%Est506.043 -1,0%MSCI World4.343 -0,1%Top 10 Crypto8,5200 -3,1%Nas22.754 +0,8%Bitcoin56.170 -0,4%Euro1,1752 -0,3%Öl71,72 +2,0%Gold4.992 +0,3%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Bayer BAY001 Rheinmetall 703000 SAP 716460 Siemens Energy ENER6Y NVIDIA 918422 Deutsche Telekom 555750 Infineon 623100 Amazon 906866 Lufthansa 823212 RENK RENK73 Microsoft 870747 Airbus 938914 Siemens 723610 DroneShield A2DMAA BASF BASF11
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX tiefrot -- Bayer profitiert von Glyphosat-Vorstoß durch Trump -- Airbus will mehr ausschütten -- Apple. DroneShield, Siemens Energy, Microsoft, TUI, Figma, eBay, SAP, Siemens im Fokus
Top News
Hardware, Software und Rekordgewinne! Analog Devices verbindet KI mit der echten Welt! Hardware, Software und Rekordgewinne! Analog Devices verbindet KI mit der echten Welt!
Ethereum und Quantencomputer: Foundation gründet eigenes Sicherheitsteam Ethereum und Quantencomputer: Foundation gründet eigenes Sicherheitsteam
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Telix Pharmaceuticals Aktie

Kaufen
Verkaufen
5,40 EUR -0,25 EUR -4,42 %
FSE
6,41 USD +0,01 USD +0,16 %
BTT
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone
KGV154,93Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA40FCQ

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS87961M1053

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolTLX

Telix Pharmaceuticals Aktien News

DatumMeistgelesen
PR NewswireTelix's Illuccix® PSMA-PET Imaging Agent Approved in Portugal
PR NewswireTelix Manufacturing Solutions (TMS) Established in Yokohama, Japan
PR NewswireTelix at ANZSNM Annual Scientific Meeting 2025
PR NewswireIlluccix China Phase 3 Study Completes Enrolment
PR NewswireTelix FAP-targeting Therapeutic Published in Thyroid Journal: Demonstrates Encouraging Efficacy
PR NewswireTelix's Illuccix® PSMA-PET Imaging Agent Approved in the Czech Republic
PR NewswireIlluccix Prostate Cancer PSMA-PET Imaging Agent Approved in Finland
PR NewswireTelix's Illuccix PSMA-PET Imaging Agent Approved in France
PR NewswireTelix's Illuccix PSMA-PET Imaging Agent Approved in France
PR NewswireIPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate
PR NewswireIPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate
PR NewswireIlluccix® Prostate Cancer PSMA-PET Imaging Agent Approved in Sweden
PR NewswireTelix Appoints Paul Schaffer as Chief Technology Officer
PR NewswireTelix Announces First Patient Dosed in First-in-Human ZOLAR Trial of TLX300-CDx in Advanced Soft Tissue Sarcoma
PR NewswireFDA Approves New Prostate Cancer Imaging Agent Gozellix®
PR NewswireIlluccix® Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization in Latin America
PR NewswireIlluccix® Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization in Latin America
PR NewswireTelix Adds Lead-212 Isotope Production Capability
PR NewswireTelix Adds Lead-212 Isotope Production Capability
PR NewswireInvestor Webinar: Telix Therapeutics Urology Showcase and Expert Forum
PR NewswireFDA Accepts BLA for TLX250-CDx (Zircaix®) for Kidney Cancer Imaging, Grants Priority Review
PR NewswireFDA Accepts BLA for TLX250-CDx (Zircaix®) for Kidney Cancer Imaging, Grants Priority Review
PR NewswireIlluccix® Prostate Cancer Imaging Agent Approved in Luxembourg
PR NewswireTelix's Illuccix® PSMA-PET Imaging Agent Approved in Norway
PR NewswireTelix 2024 Full Year Results: Record Financial Performance and Investment in Future Growth, FY2025 Guidance of up to $1.23 Billion
PR NewswireTelix 2024 Full Year Results: Record Financial Performance and Investment in Future Growth, FY2025 Guidance of up to $1.23 Billion
PR NewswireIlluccix® Approved in the United Kingdom
PR NewswireIlluccix® Approved in the United Kingdom
PR NewswireIlluccix® Approved in Denmark
PR NewswireTelix Completes Acquisition of Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform
PR NewswireTelix Completes Acquisition of RLS (USA) Inc.
PR NewswireImaginAb, Inc. Innovative Biologics-Technologieplattform von Telix erworben, um die Entdeckung von therapeutischen Wirkstoffen der nächsten Generation zu ermöglichen
PR NewswireImaginAb, Inc. Innovative Biologics Technology platform acquired by Telix to enable Next-Generation Therapeutic Assets discovery
PR NewswireImaginAb, Inc. Innovative Biologics Technology platform acquired by Telix to enable Next-Generation Therapeutic Assets discovery
PR NewswireIlluccix® Receives European Approval
PR NewswireIlluccix® Receives European Approval
PR NewswireTelix Presentation to the 43rd Annual J.P. Morgan Healthcare Conference
PR NewswireTelix Exceeds FY24 Guidance with US$142M Q4 Revenue
PR NewswireScintimun® Commercialization Partnership with Curium Pharma
PR NewswireScintimun® Commercialization Partnership with Curium Pharma

Telix Pharmaceuticals News

Telix Pharmaceuticals News: auf dieser Seite finden Sie alle Telix Pharmaceuticals News und Nachrichten zur Telix Pharmaceuticals Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Telix Pharmaceuticals News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Telix Pharmaceuticals News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.